Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells

Melanoma is an aggressive skin cancer with increasing incidence worldwide. The development of BRAF kinase inhibitors as targeted treatments for patients with BRAF-mutant tumours contributed profoundly to an improved overall survival of patients with metastatic melanoma. Despite these promising resul...

Full description

Saved in:

Bibliographic Details
Published in:	Biochimica et biophysica acta. General subjects Vol. 1861; no. 11; pp. 2980 - 2992
Main Authors:	Kozar, Ines, Cesi, Giulia, Margue, Christiane, Philippidou, Demetra, Kreis, Stephanie
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01.11.2017
Subjects:	biomarkers BRAF inhibitors Cell Line, Tumor Drug resistance Drug Resistance, Neoplasm - genetics drugs Gene Expression Profiling gene expression regulation Gene Expression Regulation, Neoplastic - drug effects genes Humans long term effects Melanoma Melanoma - drug therapy Melanoma - genetics Melanoma - pathology metastasis Microarray Analysis microRNA MicroRNAs - drug effects MicroRNAs - genetics miRNA patients Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins B-raf - antagonists & inhibitors quantitative polymerase chain reaction reverse transcriptase polymerase chain reaction skin neoplasms Skin Neoplasms - drug therapy Skin Neoplasms - genetics Skin Neoplasms - pathology synthetic biology Targeted therapy therapeutics transcriptome Transcriptome - drug effects PCSK2 Targeted therapy BRAF inhibitors WFDC1 HIF-1α Drug resistance CYR61 NRAS SESN2 CCL2 CTLA4 miRNA CHAC1 EDIL3 PC2 CE Melanoma ASNS GP BRAF MITF MAPK EMT PCA DCT AXL DOK5 NF1 XP HRE
ISSN:	0304-4165, 1872-8006
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!